Markets closed

Royalty Pharma plc

RPRX · Nasdaq

Analyst Consensus

Buy

7 analysts

$60

Current

—

Low

$66

Average

—

High

Average target implies +10.78% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across seven analysts, with a mean price target of $62 compared with the supplied ending price of $57.48. The target range cannot be characterized because both the low and high targets are unavailable, and the evidence names no analyst as most or least bullish. No analyst-specific rating or target revisions are supplied for the past week, so revision direction is also unavailable. The substantive debate visible in the company evidence is whether stronger operating performance and raised 2026 portfolio-receipts guidance outweigh the decline in attributable net income. The available analyst data do not establish whether target dispersion reflects differing views on earnings quality, guidance durability, or valuation.

Rating Actions

No individual rating actions have been captured for RPRXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

GOLDMAN SACHS

JP MORGAN SECUR

MORGAN STANLEY

TD COWEN

TIGRESS FINANCI

UBS

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Key Issues

Bullish view

Adjusted EBITDA increased to $736 million from $633 million, while quarterly earnings and revenue exceeded estimates by 3.94% and 1.52%. That supports a view that underlying operating performance remains strong despite lower reported net income.

Bearish view

Net income attributable to Royalty Pharma declined to $18 million from $32 million. Investors may therefore question whether the stronger adjusted EBITDA meaningfully translates into bottom-line earnings.

Analyst Consensus

See all

Buy

7 analysts

$60

Current

—

Low

$66

Average

—

High

Average target implies +10.78% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers